CN101060829A - Stable liquid agent for external use - Google Patents
Stable liquid agent for external use Download PDFInfo
- Publication number
- CN101060829A CN101060829A CNA2005800394178A CN200580039417A CN101060829A CN 101060829 A CN101060829 A CN 101060829A CN A2005800394178 A CNA2005800394178 A CN A2005800394178A CN 200580039417 A CN200580039417 A CN 200580039417A CN 101060829 A CN101060829 A CN 101060829A
- Authority
- CN
- China
- Prior art keywords
- liquid agent
- external use
- tocopherol
- phospholipid
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a liquid agent for external use wherein a tocopherol, a silk powder, a phospholipid such as a hydrogenated phospholipid, a carboxyvinyl polymer and water are mixed and the water content is set at 79-99% by weight. Such a liquid agent for external use is prevented from separation of the tocopherol and sedimentation of the silk powder, thereby achieving a stable dispersion state.
Description
Technical field
The present invention relates to the usability excellence, can not take place component separating or settled through the time stable liquid agent for external use.
Background technology
As everyone knows, tocopherol is owing to having antioxidation and blood circulation promoting effect, therefore for preventing the effectively aging of skin.In addition, the silk powder has the protective effect and the moisture-keeping function of skin, has slick usability simultaneously.Therefore, wait in expectation by these two kinds of compositions are mixed, thereby have the preparation of these two kinds of action effects concurrently, people's its concrete enforcement that waits in expectation.
But tocopherol is an oil content, and the silk powder is a solid constituent, therefore when making liquid agent for external use, has the separation of composition time dependent ground, settled problem.
When addressing the above problem, in order to disperse tocopherol, known have by surfactant make tocopherol and the greasy emulsifying mixture of Fructus Canarii albi wet goods, make the emulsified particle of generation be dispersed in method in the liquid agent.But for being for the liquid agent for external use of purpose to keep the skin wet, if compound lard, then the where applicable skin surface can be covered by oils and fats, has hindered moisture moving in skin, therefore preferred compound lard not.
In addition, the process for dispersing as the silk powder is generally the method for using viscosifier.But,, also have as the tocopherol of oil content and the problem of separated form water even if a powder is disperseed by viscosifier.
In addition, in order to improve scaly dry skin, wrinkle, dry and cracked, disclose the skin preparations for extenal use (patent documentation 1) that contains hydrolyzed silk protein and Sargassum extract, can enumerate the astringent that contains hydrolyzed silk protein aqueous solution, CVP Carbopol ETD2050 and water particularly or contain the oil-in-water emulsion of tocopherol, hydrolyzed silk protein aqueous solution, hydrogenated soya phosphatide matter, CVP Carbopol ETD2050 and water.But, hydrolyzed silk protein and silk powder and inequality.
Patent documentation 1: TOHKEMY 2003-176218 communique
Summary of the invention
Problem of the present invention for obtain to contain a tocopherol and a powder, usability excellence and have can not separate or settled through the time stable dispersity liquid agent for external use.
Various researchs have been carried out in order to solve above-mentioned problem, found that, by in the liquid agent for external use of the water that contains tocopherol, silk powder and 79～99 weight %, adding phospholipid and CVP Carbopol ETD2050, the liquid agent for external use that can obtain the usability excellence, have stable dispersity as preparation.
That is, the invention provides and contain tocopherol, silk powder, phospholipid, CVP Carbopol ETD2050 and water, the content of water is the liquid agent for external use of 79～99 weight %.From other viewpoints, the invention provides the method for in containing the liquid agent for external use of water, stably disperseing tocopherol and silk powder, it is characterized in that, mixed phosphatide matter and CVP Carbopol ETD2050 in above-mentioned liquid agent for external use, and make the content of water reach 79～99%.
The specific embodiment
Liquid agent for external use of the present invention is the waterborne liquid agent that contains tocopherol, silk powder, phospholipid, CVP Carbopol ETD2050 and water.
Tocopherol among the present invention comprises tocopherol, Tocopheryl derivatives and their salt.For example d-alpha-tocopherol, dl-alpha-tocopherol, d-α-tocopheryl acetate, dl-α-tocopheryl acetate, dl-α-nicotinic acid tocopherol, succinic acid dl-alpha-tocopherol calcium, succinic acid d-alpha-tocopherol, succinic acid dl-alpha-tocopherol etc.The combined amount of tocopherol with respect to the liquid agent for external use total amount be preferably 0.01～2 weight %, more preferably 0.02～1 weight %, be preferably 0.05～0.5 weight % especially.If surpass 2 weight %, then be clamminess, the usability variation; If less than 0.01 weight %, then in order to obtain effectiveness as effective ingredient such as antioxidation and blood circulation promoting effects, must the coating of volume ground, therefore preferred above-mentioned scope.
Silk powder among the present invention is meant the water-insoluble proteinic powder of the formation thin,tough silk fiber of gained from the cocoon of silkworm, is main component with the fibroin.As the silk powder for example (as commercially available product) can enumerate シ Le Network ゲ Application G powder (a ball Off ア Le コ ス), シ Le Network ID powder-K-50 (bright dipping petrochemistry).Said silk powder can also be the surface have been carried out modifying give the product of various additional effect among the present invention.For example (as commercially available product) can enumerate シ Le Network ID powder-A-705 (bright dipping petrochemistry), シ Le Network ID powder-S-702 (bright dipping petrochemistry), シ Le Network ID powder-L-710 (bright dipping petrochemistry).Silk powder combined amount with respect to the liquid agent total amount be preferably 0.01～10 weight %, more preferably 0.1～5 weight %, be preferably 0.3～5 weight % especially.If surpass 10 weight %, the dry sense of touch that then comes from powder can strengthen, lubricated sense reduces; If less than 0.01 weight %, then render a service in order to obtain, must the coating of volume ground, therefore preferred above-mentioned scope.
Phospholipid of the present invention is meant the complex lipid that contains the phosphoric acid residue, can enumerate natural phospholipid matter, synthetic phospholipid matter, the phospholipid of natural origin is carried out hydrotreated hydrogenated phospholipid matter etc.
As natural phospholipid matter, phospholipid that for example can enumerate phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, Phosphatidylserine, phosphatidylinositols, LYSO-PHOSPHATIDYLCHOLINE LYSOPC, sphingomyelins, Ovum Gallus domesticus Flavus lecithin, soybean lecithin, from microorganisms such as escherichia coli, extracts etc.As commercially available product COATSOME NC-50 (NOF), presome (Japan refines) etc. are arranged.
As synthetic phospholipid matter, for example can enumerate dioleoyl phospholipid phatidylcholine, two Laurel phosphatidyl cholines, dimyristoyl phosphatidyl choline, dipalmitoyl phosphatidyl choline, distearoyl phosphatidylcholine, palmityl oleoyl phosphatidylcholine etc.As commercially available product, COATSOMEMC-2020, COATSOME MC-4040, COATSOME MC-6060, COATSOME MC-8080, COATSOME MC-8181, COATSOME MC-6081 (NOF) etc. are arranged.
As hydrogenated phospholipid matter, for example can enumerate hydrogenated soya phosphatide matter, hydrogenation egg yolk lecithin matter, hydrogenated phospholipid phatidylcholine, hydrogenated phospholipid acyl serine etc.As commercially available product, can enumerate レ シ ノ one Le S-10, レ シ ノ one Le S-10E, レ シ ノ one Le S-10M, レ シ ノ one Le S-10EX, レ シ ノ one Le S-PIE (daylight ケ ミ カ Le ズ), COATSOME NC-21 (NOF), Phospholipon 100H, Phospholipon 90H, Phospholipon 80H, Phospholipon 90G (phospholipid) etc.
In these phospholipid, preferred hydrogenated phospholipid matter.Specifically, be preferably the content of hydrogenated phospholipid phatidylcholine more than 70%, preferably more than 80%, more preferably in the hydrogenated phospholipid matter more than 90%.The hydrogenated phospholipid phatidylcholine the viscosity that improves the aqueous liquid agent for external use, obtain aspect the stable dispersity preferred.
Among the present invention, phospholipid can make up more than a kind or 2 kinds and use.The combined amount of phospholipid with respect to the total amount of liquid agent for external use be preferably 0.01～5 weight %, more preferably 0.1～2 weight %, be preferably 0.3～1 weight % especially.When above 5 weight % or less than 0.01 weight %, often be difficult to obtain the stable dispersion effect of tocopherol.
CVP Carbopol ETD2050 among the present invention is meant the polymerizing acrylic acid thing with carboxyl.As CVP Carbopol ETD2050, commercially available product for example can be enumerated カ one ボ Port one Le 980, ETD2050, ウ Le ト レ ッ Star 10 (the above NOVEON of being production), Ha イ PVC ス ワ コ one, シ Application レ Application K, シ Application レ Application L, シ Application レ Application M (above for already producing with the pure pharmaceutical worker of light) etc.The combined amount of CVP Carbopol ETD2050 with respect to the total amount of liquid agent for external use be preferably 0.005～4 weight %, more preferably 0.01～1 weight %, be preferably 0.02～0.5 weight % especially.If surpass 4 weight %, then send out wrinkle, the grow that is clamminess, the usability variation; If less than 0.005 weight %, then often be difficult to obtain the dispersion effect of target.
The combined amount of the water that uses among the present invention is adjusted according to the amount of other intermixtures, with respect to the liquid agent for external use total amount, be preferably 79～99 weight %, more preferably 85～98 weight %, be preferably 90～96 weight % especially.If surpass 99 weight %, then be difficult to obtain the effect of tocopherol or silk powder; If less than 79 weight %, then often be difficult to give skin with lubricated fully.
Need to prove that said liquid agent for external use is meant the liquid agent that is applicable to skin here.For example can enumerate the liquid agent of using in order to replenish insufficient moisture, maintenance smooth skin state to skin.Liquid agent for external use of the present invention does not preferably mix composition required in this invention oil content in addition when being used for this purposes.But, only otherwise damage effect of the present invention, also can contain a spot of oil content.
Liquid agent for external use of the present invention can contain effective ingredient, nertralizer, preservative agent, stabilizing agent and the wetting agent etc. beyond the tocopherol, also can not contain.In addition, the material that can contain also is not limited to above-mentioned substance.
Can enumerate antiinflammatories such as the potassium salt of glycyrrhizic acid or ammonium salt as other effective ingredient beyond the tocopherol, the hydryllin such as diphhydramine hydrochloride that are used for the treatment of pruritus, anti-acne agents such as ピ オ ニ Application, the whitening agent of ascorbic acid or ascorbic acid derivates etc., wetting agents such as hyaluronic acid, ア Le ゲ コ ロ イ De, trehalose etc.
As nertralizer, can enumerate organic acid such as citric acid, phosphoric acid, tartaric acid, lactic acid, mineral acids such as hydrochloric acid, alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, amines such as triethanolamine, diethanolamine, diisopropanolamine (DIPA) etc.
As preservative agent, can enumerate Para Hydroxy Benzoic Acid esters, chlorination benzalkonium bromide etc.
As stabilizing agent, can enumerate sodium sulfite, sodium sulfite, dibenzylatiooluene, Butylated hydroxyanisole, edetic acid etc.
As wetting agent, can enumerate polyhydric alcohol such as glycerol, ethylene glycol, propylene glycol, 1,3 butylene glycol, Isopropanediol, Polyethylene Glycol.
The pH of liquid agent for external use of the present invention is from aspects such as the segregational stability of preparation and skin irritations, is preferably pH 4～8, pH 5.5～6.5. more preferably usually
The viscosity of liquid agent for external use of the present invention is preferably 0.05Pas～1Pas, 0.1Pas～0.5Pas more preferably.If less than 0.05Pas, then sedimentation can take place in silk powder and phospholipid micropartical.If surpass 1Pas, then often mobile reduction, extension variation.Viscosity for example can use cone-plate type rotary viscosity agent AR1000-N (TA イ Application ス ト Le メ Application ト) to measure.
Liquid agent for external use of the present invention can for example can be heated to phospholipid and tocopherol more than 80 ℃ in polyhydric alcohol by the usual way manufacturing, it is fully dissolved after, mix equably with water, add silk powder and CVP Carbopol ETD2050 then, until mix homogeneously, thus modulation.
Embodiment
Below enumerate embodiment and more specifically describe the present invention, but the present invention is not limited to these embodiment.
[embodiment 1]
With 0.2g tocopheryl acetate and 0.5g hydrogenated soya phosphatide matter (Phospholipon 90H: phospholipid) join in the 5g 1,3 butylene glycol, fully stir down, mix at 80 ℃.In this solution, add the 30g Purified Water and fully stir, mix (modulating liquid A).
In the 60g Purified Water, add 0.05g CVP Carbopol ETD2050 (シ Application レ Application L :), 0.01g edetate sodium, 0.1g to the Para Hydroxy Benzoic Acid methyl ester, fully stir, mix with the pure pharmaceutical worker's industry of light.An amount of potassium hydroxide that adds as nertralizer in this solution, making pH is 6, fully stir, after the mixing, add modulating liquid A and 0.5g silk powder (シ Le Network ゲ Application G powder: a ball Off ア Le コ ス), fully stir, after the mixing, under reduced pressure remove bubble, add entry, making total amount is 100g, obtains the aqueous liquid agent for external use.
[comparative example 1-5]
By the method identical with embodiment 1, use the composition shown in the table 1, obtain the liquid agent for external use of comparative example 1～5.Adjust combined amount, make that employed various viscosifier reach viscosity of the same race (about 0.3Pas) in embodiment 1 and each comparative example.Need to prove that the sodium alginate of comparative example 3 uses the hydroxyethyl-cellulose of キ ミ カ ア Le ギ Application I-S (キ ミ カ), comparative example 4 to use the hydroxypropyl methylcellulose 2208 of HEC CF-Y (refining in the Sumitomo), comparative example 5 to use メ ト ロ one ズ 90SH-15000 (SHIN-ETSU HANTOTAI's chemical industry).
[test example]
In order to study the appearance stability of synthetic preparation, each preparation of embodiment 1 and comparative example 1～5 is filled in the vial, affirmation 40 ℃ preserve down 1 week the back, 2 week back and after 2 months, 60 ℃ preserve down 1 week the back, 2 week the back have or not cosmetic variation (separating or the sedimentation of silk powder of tocopherol) after with 1 month.To not regard sb. as an outsider see variation person be shown as zero, will have cosmetic variation person be shown as *.
In addition, use cone-plate type rotating cylinder viscometer AR1000-N (TA イ Application ス ト Le メ Application ト) to measure viscosity by following condition.Connection tube: 6cm, 2 ° of plates, 20 ℃, friction stree 2Pa.
Table 1 (g)
| Embodiment 1 | Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | Comparative example 5 | ||
| Tocopherol | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |
| The silk powder | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | |
| Hydrogenated soya phosphatide matter | 0.6 | - | 0.6 | 0.6 | 0.6 | 0.6 | |
| CVP Carbopol ETD2050 | 0.06 | 0.06 | - | - | - | - | |
| Sodium alginate | - | - | - | 0.72 | - | - | |
| Hydroxyethyl-cellulose | - | - | - | - | 0.6 | - | |
| Hydroxypropyl methylcellulose 2208 | - | - | - | - | - | 0.75 | |
| Edetate sodium | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| 1,3 butylene glycol | 5 | 6 | 6 | 6 | 5 | 5 | |
| To the Para Hydroxy Benzoic Acid methyl ester | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Sodium hydroxide | In right amount | In right amount | - | - | - | - | |
| Water | Total amount 100g | Total amount 100g | Total amount 100g | Total amount 100g | Total amount 100g | Total amount 100g | |
| Viscosity Pas | 0.3 | 0.2 | Less than 0.1 | 0.3 | 0.4 | 0.3 | |
| The outward appearance of just having modulated | ○ | × | × | ○ | ○ | ○ | |
| 40℃ | Outward appearance after 1 week | ○ | × | × | × | × | × |
| Outward appearance after 2 weeks | ○ | × | × | × | × | × | |
| Outward appearance after 2 months | ○ | × | × | × | × | × | |
| 60℃ | Outward appearance after 1 week | ○ | × | × | × | × | × |
| Outward appearance after 2 weeks | ○ | × | × | × | × | × | |
| Outward appearance after 1 month | ○ | × | × | × | × | × | |
When not having mixed phosphatide matter in the liquid agent for external use that is containing tocopherol, silk powder and water (comparative example 1), in firm synthetic preparation, as seen separate (tocopherol).The preparation (comparative example 2) that does not mix CVP Carbopol ETD2050 is in the sedimentation of the visible silk in modulation back powder just.
In addition, though used the macromolecule outside the CVP Carbopol ETD2050 of sodium alginate (comparative example 3), hydroxyethyl-cellulose (comparative example 4), hydroxypropyl emthylcellulose (comparative example 5) etc. that viscosity is adjusted to about 0.3Pas, but all results are at 40 ℃ of 1 week of preservation or 1 week back visual appearance variations under 60 ℃ down, poor stability.
But, the preparation (embodiment 1) of mixed phosphatide matter and CVP Carbopol ETD2050 in the liquid agent for external use that contains tocopherol, silk powder and water is even if after preserving 1 month under 60 ℃ or after preserving 2 months under 40 ℃, there is no cosmetic variation, shown good stable.
Need to prove, when estimating the usability of embodiment 1, can give salubrious sense and moist feeling, can also obtain good usability.
Industrial applicability
By the present invention, can be with tocopherol and the silk powder of difficulty stably are dispersed in the liquid agent at present.
Claims (2)
1. liquid agent for external use, it contains tocopherol, silk powder, phospholipid, CVP Carbopol ETD2050 and water, and the content of water is 79～99 weight %.
2. tocopherol and silk powder stably are dispersed in the method in the liquid agent for external use that contains water, it is characterized in that, be mixed with phospholipid and CVP Carbopol ETD2050 in the described liquid agent for external use, and the content of water is 79～99 weight %.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP334252/2004 | 2004-11-18 | ||
| JP2004334252A JP2006143630A (en) | 2004-11-18 | 2004-11-18 | Stable liquid for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101060829A true CN101060829A (en) | 2007-10-24 |
Family
ID=36407008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800394178A Pending CN101060829A (en) | 2004-11-18 | 2005-11-09 | Stable liquid agent for external use |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2006143630A (en) |
| KR (1) | KR100826759B1 (en) |
| CN (1) | CN101060829A (en) |
| TW (1) | TW200621303A (en) |
| WO (1) | WO2006054465A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010143848A (en) * | 2008-12-18 | 2010-07-01 | Kao Corp | Cosmetic |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0623256A (en) * | 1992-06-29 | 1994-02-01 | Nikko Kemikaruzu Kk | Lecithin emulsifier and o/w emulsion |
| JP3682614B2 (en) * | 1998-08-19 | 2005-08-10 | 株式会社コーセー | Aqueous cosmetics |
| JP2000212064A (en) * | 1999-01-26 | 2000-08-02 | Sekisui Chem Co Ltd | Bath agent composition containing silk powder |
| JP2002003338A (en) * | 2000-06-26 | 2002-01-09 | Kose Corp | Oil-in-water type emulsion cosmetic |
| JP3791775B2 (en) | 2001-12-12 | 2006-06-28 | 株式会社相生発酵 | Topical skin preparation |
| JP2003267854A (en) * | 2002-03-15 | 2003-09-25 | Kose Corp | Bleaching cosmetic |
| JP3889657B2 (en) * | 2002-04-24 | 2007-03-07 | クローダジャパン株式会社 | Dimer diol derivative and composition containing dimer diol derivative |
| JP2004123575A (en) * | 2002-09-30 | 2004-04-22 | Rohto Pharmaceut Co Ltd | Gel-like composition for external use |
| JP2004250433A (en) * | 2003-01-28 | 2004-09-09 | Kanebo Ltd | Cosmetic preparation |
| JP2004285016A (en) * | 2003-03-24 | 2004-10-14 | Kose Corp | Unevenness-corrective cosmetic |
-
2004
- 2004-11-18 JP JP2004334252A patent/JP2006143630A/en active Pending
-
2005
- 2005-11-09 KR KR1020077013516A patent/KR100826759B1/en not_active IP Right Cessation
- 2005-11-09 CN CNA2005800394178A patent/CN101060829A/en active Pending
- 2005-11-09 WO PCT/JP2005/020520 patent/WO2006054465A1/en active Application Filing
- 2005-11-16 TW TW094140341A patent/TW200621303A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR100826759B1 (en) | 2008-04-30 |
| TW200621303A (en) | 2006-07-01 |
| WO2006054465A1 (en) | 2006-05-26 |
| JP2006143630A (en) | 2006-06-08 |
| KR20070086239A (en) | 2007-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101705779B1 (en) | Silicone paste compositions | |
| CN1109754A (en) | Argatroban consentrated aqueous solution | |
| JP5203472B2 (en) | Re-epithelialized pharmaceutical composition comprising xanthan gum | |
| AU2016200292A1 (en) | Ophthalmic oil-in-water emulsions containing cyclosporine or a polyphenol | |
| CN1153474A (en) | Stable oil-in-water emulsions incorporating taxine (taxol) and method of making same | |
| CN1931164A (en) | Nanometer miconazole nitrate emulsion medicine and its prepn process | |
| HUE029786T2 (en) | Ophthalmic emulsion | |
| JP2015506978A (en) | Silicone emulsion for delivery of health care active ingredients | |
| AU2009301275A1 (en) | Modified release emulsions for application to skin or vaginal mucosa | |
| CN1357032A (en) | Metal working fluids | |
| CN102397168A (en) | Flexible nanoliposomes with charges for cosmetics and preparation method thereof | |
| JP2013538188A (en) | Two drug delivery using silicone gel | |
| CA2764326A1 (en) | Therapeutic ophthalmic emulsions | |
| CN101060829A (en) | Stable liquid agent for external use | |
| CN1416334A (en) | Lipid carrier | |
| US20180036236A1 (en) | Ionic nanovesicle suspension and biocide prepared therefrom | |
| López-Cano et al. | Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection | |
| CN1158995C (en) | Fluorometholone suspension eye drops | |
| JPWO2018105678A1 (en) | Ophthalmic composition | |
| CN1711095A (en) | Composition for restoring damaged skin | |
| Al-Ogaidi | Improving oral intake of essential oil blends using a novel formulation of biodegradable chitosan/lecithin nanoparticles | |
| CN1298325C (en) | Stabilized oil-in-water emulsion of matrine alkaloid for venous purpose and production thereof | |
| FR2737135A1 (en) | FLUORINATED CONTINUOUS PHASE INVERSE GELS | |
| JP6283570B2 (en) | Method for producing polyisobutylene emulsion | |
| CN1202798C (en) | Water in oil emulsified composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |